Recently, Liban Pharmaceuticals, an innovative drug company focused on kidney diseases, has once again submitted a listing application to the Hong Kong Stock Exchange, marking its second attempt following the lapse of its initial application in October 2025. As one of the few biopharmaceutical companies in China specializing in chronic kidney diseases, Liban carries the distinction of potentially being the first kidney disease-focused stock on the Hong Kong market. It has attracted investment from top-tier capital such as Tencent, Lilly Asia Ventures, and GIC, with a pre-IPO valuation reaching RMB 3.779 billion.
However, behind this seemingly promising capital story lies the reality of cumulative losses exceeding RMB 1.45 billion over the company's eight-year history, consistently negative operating cash flow, a core product yet to receive approval, and uncertain future commercial capabilities. Its path to an IPO remains fraught with uncertainty.
**Losses Exceed 1.4 Billion in Three Years, Cash Reserves Sufficient for Only 15 Months**
Financially, the prospectus shows that from 2023 to 2025, the company recorded net losses of RMB 365 million, RMB 335 million, and RMB 752 million respectively, resulting in a cumulative three-year loss of RMB 1.452 billion. The primary source of these losses is substantial R&D investment, with Liban's R&D expenses reaching RMB 235 million and RMB 373 million in 2024 and 2025 respectively.
Furthermore, significant increases in administrative and selling expenses have exacerbated the losses. In 2025, the company's administrative expenses surged from RMB 62.113 million in 2024 to RMB 251 million, an increase of 304.6%, primarily due to a substantial rise in share-based payment expenses. Selling expenses also grew from RMB 15.171 million in 2024 to RMB 36.337 million.
Amidst these sustained losses, the company's cash flow is under clear pressure. The prospectus indicates that from 2023 to 2025, the net cash flow from operating activities was -RMB 302 million, -RMB 250 million, and -RMB 288 million respectively, representing significant net outflows for three consecutive years. As of December 31, 2025, the company's cash and cash equivalents stood at RMB 358 million.
Based on the 2025 net operating cash outflow rate of RMB 288 million, the existing cash reserves can only support approximately 15 months of operations. Considering the continued increase in R&D investment and the expansion of the commercialization team, the actual supportable period may be even shorter.
**Business Reliance on a Single Licensed Product**
In terms of business, Liban's product pipeline is highly singular. To date, the company has only one commercialized product, Mircera. This product is a long-acting erythropoiesis-stimulating agent licensed from Roche in October 2023 for treating anemia associated with chronic kidney disease. In 2024 and 2025, Mircera generated sales revenue of RMB 6.5 million and RMB 30.556 million respectively for the company, accounting for 100% of its total revenue.
The risks associated with reliance on a single product are evident. Firstly, the company holds no pricing or production rights for Mircera, earning only modest promotion fees. Secondly, the commercialization rights agreement for Mircera is not permanent and carries risks related to expiration or changes in terms.
Additionally, Mircera faces increasingly fierce market competition. Currently, the Chinese renal anemia drug market is primarily composed of two major product categories: Erythropoiesis-Stimulating Agents (ESAs) and Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs). Among these, HIF-PHI products like roxadustat and daprodustat are rapidly capturing market share due to their oral convenience and significant efficacy. According to Frost & Sullivan data, the Chinese renal anemia drug market reached RMB 5.9 billion in 2024 and is expected to grow to RMB 10.4 billion by 2035, with a compound annual growth rate of only 5.3%. In this slow-growth market, the sales growth potential for Mircera is limited.
**Core Pipeline Asset Lacks Clear Advantage; Equity Structure Raises Regulatory Scrutiny**
Regarding its pipeline, Liban's current clinical and preclinical portfolio consists of one core product, AP301, and six other candidate products. Notably, most of these are acquired from external sources.
For instance, AP301's global rights were acquired in stages in 2018 and 2021 from the US company Vidasym; AP306 is a pan-phosphate transporter inhibitor licensed from Japan's Chugai Pharmaceutical; AP308 is a candidate drug for diabetic kidney disease introduced from an external source. The company's self-developed pipeline assets, such as AP303, AP304, AP305, and AP307, have not yet entered Phase II clinical trials, remain far from market approval, and are unlikely to generate revenue in the short term.
Among these, the core product AP301 is an oral phosphate binder for treating hyperphosphatemia. It has completed the Chinese Phase III registration clinical trial and is expected to submit a New Drug Application in the second quarter of 2026.
Currently, the domestic hyperphosphatemia drug market is dominated by four categories: calcium-containing phosphate binders like calcium carbonate and calcium acetate; non-calcium-containing phosphate binders like sevelamer carbonate and lanthanum carbonate; iron-based phosphate binders like sucroferric oxyhydroxide; and novel targeted drugs like tenapanor. Among these, calcium-containing binders still hold the majority market share due to their low cost; non-calcium-containing binders are gradually increasing their market share due to better safety profiles; iron-based binders and novel targeted drugs are recently launched products experiencing rapid growth.
Liban's AP301 belongs to the non-calcium-containing phosphate binder category, with direct competitors including sevelamer carbonate, lanthanum carbonate, and sucroferric oxyhydroxide. The prospectus states that AP301 features higher phosphate-binding capacity, can be swallowed without chewing, has low volume expansion in digestive fluid, and exhibits no systemic absorption, potentially making it a best-in-class product. However, compared to competitors like sevelamer carbonate, AP301's advantages are not particularly pronounced.
Clinically, based on the disclosed Chinese Phase III trial results in the prospectus, at the 12-week treatment mark, AP301 only met the non-inferiority standard compared to sevelamer carbonate in reducing serum phosphorus levels, with reductions from baseline of -0.72 mmol/L and -0.70 mmol/L for the two groups respectively. At week 52, the serum phosphorus target achievement rate for the AP301 group was 66.7%, slightly higher than the 59% for the sevelamer carbonate group.
Regarding pricing, both sevelamer carbonate and lanthanum carbonate are already included in the National Reimbursement Drug List and have undergone multiple rounds of volume-based procurement, leading to significant price reductions. For example, the procurement price for sevelamer carbonate is approximately RMB 1.5 per tablet, with a daily treatment cost around RMB 6; lanthanum carbonate's procurement price is about RMB 2 per tablet, with a daily treatment cost around RMB 8. As a new drug, AP301's initial market price is inevitably high. Even if it gains reimbursement list inclusion, it may require substantial price cuts, impacting its profitability.
**Governance and Compliance Issues**
Beyond financial and business challenges, Liban's corporate governance and compliance issues warrant attention. In January 2026, the China Securities Regulatory Commission raised seven supplemental clarification items regarding the company's initial IPO application, requesting detailed explanations on matters such as the largest shareholder's situation, equity structure, and related-party transactions.
Regarding the equity structure, the prospectus shows that Liban has no single controlling shareholder. The founders and parties acting in concert collectively hold 24.50% through multiple platforms, forming the single largest shareholder group. Tencent holds 11.732%, making it the second-largest shareholder, and Guojin holds 9.6166%, the third-largest. This dispersed equity structure could potentially lead to decision-making disagreements affecting operational efficiency.
More notably, the CSRC requested the company to "supplement explanations regarding the situation of the company's largest shareholder and shareholders with significant influence on the company, with reference to requirements for controlling shareholders and actual controllers," and to "supplement explanations regarding the reasons and specific circumstances for ceasing the look-through of overseas enterprises and funds among the upper-level investors of the company's major shareholders, and whether there exist domestic entities or entities prohibited by laws and regulations from holding shares." This indicates regulatory suspicion regarding whether there might be hidden actual controllers behind the company's equity structure or shareholding entities that do not comply with regulations.
In summary, although Liban Pharmaceuticals carries the potential distinction of being the "first kidney disease stock on the Hong Kong market" and has support from prominent investors, it faces multiple concurrent challenges: persistent financial losses, pipeline reliance on external acquisitions, a lack of clear competitive advantage for its core product, intense market competition, and unresolved regulatory concerns. Its path to listing remains beset with numerous obstacles.
Comments